Immunome Inc

Immunome, Inc. (Nasdaq: IMNM) is a clinical-stage targeted oncology company developing first-in-class and best-in-class cancer therapies, including antibody-drug conjugates (ADCs) and radioligand therapies. It currently generates no product or collaboration revenue.

Its lead candidate, varegacestat, is an investigational gamma secretase inhibitor for desmoid tumors, supported by the Phase 3 RINGSIDE study. The U.S. FDA has accepted its New Drug Application, with a PDUFA target action date of April 28, 2027, and the EMA has validated its Marketing Authorization Application.

The clinical pipeline also includes:
- IM-1021, a ROR1-targeted ADC in Phase 1 for B-cell non-Hodgkin lymphoma.
- IM-1617, a solid tumor ADC in Phase 1.
- IM-3050, a FAP-targeted radioligand therapy in Phase 1.
- IM-1340, an IND-cleared, potential first-in-class solid tumor ADC.

IM-1617 and IM-1340 use the company's proprietary TOP1 inhibitor payload, HC74. The company is also advancing preclinical ADCs, including IM-1335 (IND planned for late 2026) and additional undisclosed solid tumor programs targeting INDs in 2027 and beyond. Updated Nov 9, 2026